Research and Development in the Physical, Engineering, and Life Sciences

NAICS 2022 code 54171 — United States (rollup primer)

---

1. Overview

This is the United States' research-and-development-for-hire industry — the establishments whose main line of business is doing R&D as a paid service, not making a product. When a drug company, a defense agency, an energy department, an automaker, or a venture-backed startup wants to invent, test, and de-risk something new but does not want to build and staff the lab itself, work flows to the firms in this code. The North American Industry Classification System (NAICS) code 54171 is the "industry" level that gathers three narrower R&D niches under one roof: nanotechnology (541713), biotechnology except nanobiotechnology (541714), and everything else in the physical, engineering, and life sciences (541715).[1]

The single most important thing to understand about this level is what it leaves out. R&D is usually a cost center inside another company. When an automaker, a chip maker, or a big pharmaceutical firm runs its own labs, that spending is counted under its industry — auto manufacturing, semiconductor manufacturing, pharmaceutical manufacturing — not here. This code captures only the slice of American research that is bought and sold as a stand-alone service: the merchant R&D market. That makes it a much smaller number than "how much R&D America does," but a much cleaner window into a distinct, high-wage, and structurally growing services economy.[5]

Why it matters to an investor — and how you get exposure — differs sharply across the three children, which is the real subject of this primer:

• The public-market door is narrow and uneven. There is no single listed company or fund that is a clean proxy for the whole code. Biotech is the most investable in public markets (deep pools of listed clinical-stage companies plus exchange-traded funds); the "everything else" bucket offers listed contract research organizations and federal science contractors; nanotechnology has almost no credible public pure-play at all.
• The private door is where most of the activity lives — venture capital (VC), private equity (PE), corporate partnerships, university spinouts, and large non-profit research institutes that cannot be bought at any price.

The distinctive value of looking at the level rather than the individual codes is the contrast: how the three children differ in size, growth direction, who owns them, how concentrated they are, and how an investor can actually touch them. That contrast is Section 2.

---

2. What's inside — the three children and how they differ

The three child industries replaced the older 2012 R&D codes; nanotechnology and biotechnology were carved out into their own codes in the 2017 NAICS revision, leaving 541715 as the large catch-all.[1] They share one economic DNA — selling high-skill technical labor and lab capacity by the project — but they differ in almost every way that matters to an investor.

Contrast table

Acronyms: HHI = Herfindahl-Hirschman Index, a standard 0–10,000 concentration gauge (regulators treat ~1,500+ as "concentrated"); CR4 = combined revenue share of the four largest firms; CRO = contract research organization; VC = venture capital; PE = private equity; ETF = exchange-traded fund.[2][3][4]

How to read the contrast. Three patterns stand out:

1. 541715 is the whale. The unglamorous catch-all — contract research organizations that run drug trials, engineering-research shops, energy and defense labs, environmental and agricultural research — is nearly three-fifths of the level's revenue and almost two-thirds of its jobs.[4] The two "hyped" codes, nano and biotech, are the minority of the industry by every hard measure.

2. Concentration runs opposite to size. The smallest child, nanotechnology, is the most concentrated (a handful of larger labs plus a fat tail of pre-revenue startups), while the two larger children are among the most fragmented industries in the entire economy — thousands of small labs, no dominant firm.[2][3][4] That means the "average" firm looks very different depending on which child you are in.

3. Investability is inverted from the science headlines. Nanotechnology gets the futuristic press but is nearly impossible to own cleanly in public markets; the mundane contract-research and federal-services businesses in 541715, and the deep public biotech complex in 541714, are where listed exposure actually exists.

---

3. How big it is (this level's rollup figures)

Our ground-truth federal figures for the whole 54171 industry. They come from two different Census programs and two different years, so treat them as a set of readings, not one continuous income statement.[2]

The rollup reconciles cleanly. The three children's establishment counts, employment, payroll, and 2022 receipts add up almost exactly to the level totals above — a useful integrity check that the children are mutually exclusive slices of the same whole. (Firm counts are the exception: the children sum to ~16,700 firms while the level reports 16,450, because a single firm can operate establishments in more than one child code and is counted once at the parent level.[3]) The pooled level is also more fragmented than any single child — HHI 62.2, below nano's 551, biotech's 91, and the catch-all's 117 — because combining three different research fields dilutes any one firm's share.[2][3]

This is a genuinely high-wage industry. ~$150 billion of payroll across ~957,000 workers is roughly $156,000 per employee — a workforce of PhD scientists, engineers, statisticians, clinicians, and clinical-research staff, not low-wage labor.[2]

The undercount caveat is large — and it runs in the same direction for all three children. The $331 billion of receipts is only R&D sold as a service. It is a small fraction of all research performed in the United States, for four reasons:

• In-house corporate R&D is elsewhere. A carmaker's, chip maker's, or drug company's own labs are classified under the parent's manufacturing industry, not here. This is the biggest gap by far.[4]
• Universities and government/national labs are excluded — university research sits under education, federal labs under public administration — even though together they perform an enormous share of U.S. science.[2]
• County Business Patterns omits the self-employed, no-payroll operators, and most government workers, so the fat tail of one- and two-person specialist labs (especially in nanotechnology) is under-counted.[2]
• Equity-funded, pre-revenue firms report little or no "receipts" even while employing hundreds — a clinical-stage biotech or a nano startup living on investor capital barely registers in a revenue-based measure.[3]

For scale: total U.S. R&D reached about $937 billion in 2023, of which businesses performed roughly $722 billion — the vast majority of it in-house and booked under other industry codes.[5] Read the $331 billion here as "the market for R&D you can hire someone else to do," not as the nation's research budget. The activity called "R&D" is several times larger than this industry.

---

4. The investable universe — where value concentrates across the children

There is no pure public play on the whole code, and the listed names below are proxies whose full revenue never maps cleanly to any one NAICS code. Where you can put money differs by child, and value concentrates in three very different places. (Tickers and scale figures appear here and in Section 10 only.)

Biotechnology (541714) — the deepest public and private pool. Biotech is one of the most heavily traded sectors in public markets. The listed face is hundreds of small clinical-stage and platform companies (e.g., Alnylam/ALNY, CRISPR Therapeutics/CRSP, Recursion/RXRX), reached most simply through two ETFs — XBI (equal-weighted, the closest proxy for the research layer) and IBB (cap-weighted, skewed toward commercial giants).[3-biotech] The largest "biotech" names most people know (Eli Lilly/LLY, Amgen/AMGN, Gilead/GILD, Vertex/VRTX) are technically pharmaceutical manufacturers and sit outside the code. The private layer is where most 541714 firms actually live: venture capital put an estimated ~$38 billion into biotech globally in 2025, and company-builders such as Flagship Pioneering and ARCH Venture Partners create whole portfolios of platforms.[3-biotech]

Physical/engineering/life sciences (541715) — two clean listed clusters. The most direct listed exposure to R&D outsourcing is the clinical-CRO complex: IQVIA (IQV), ICON (ICLR), Charles River (CRL, more preclinical/cyclical), Medpace (MEDP), Fortrea (FTRE), Inotiv (NOTV). The physical-sciences and engineering half shows up in federal science-and-engineering contractors: Leidos (LDOS), SAIC, Amentum (AMTM), Parsons (PSN), KBR, Jacobs (J), Exponent (EXPO). Broader platforms (Thermo Fisher/TMO, which owns the PPD CRO; Labcorp/LH) embed R&D inside much larger enterprises. Much of the mid-tier is PE-owned (Parexel, Syneos, Peraton), and the field's strategic anchors — non-profit institutes such as Battelle, SRI International, Southwest Research Institute, RTI, and MITRE — cannot be bought at any price.[4]

Nanotechnology (541713) — almost nothing to own directly. There is no large, profitable public company whose sole business is nanotech R&D. Direct pure-plays are small, speculative micro-caps (Nanophase/NANX, Nanoco/NANO, Applied DNA/APDN). The credible public route is indirect: the semiconductor-equipment, metrology, and scientific-instrument makers that supply and commercialize nanoscale work — Applied Materials (AMAT), Lam Research (LRCX), KLA (KLAC), Onto Innovation (ONTO), Bruker (BRKR), Veeco (VECO) — plus diversified materials giants (BASF, DuPont). The genuine nano R&D lives in private startups (Sila, Group14, Forge Nano) reachable only through venture and growth capital.[6]

Bottom line for the reader. If you want listed exposure to this industry, biotech ETFs and the CRO/federal-services complex are the realistic doors; if you want exposure to nanotechnology specifically, you are mostly limited to indirect "picks and shovels" or private capital. Across all three, the deepest and most genuine exposure is private — and long-dated.

---

5. How the money works

At every level this is a people-and-projects business: the cost base is overwhelmingly salaries for scientists, engineers, and clinical staff, plus (for the lab-heavy segments) expensive capital equipment. Margin comes from keeping that talent on paid work. But the revenue models split into three recognizable types, and which one dominates depends on the child:

• Contract and service revenue (the workhorse, biggest in 541715). Full-service CROs and engineering-research shops sell multi-year contracts and recognize revenue as work is delivered. The gauges that matter are bookings (net new awards), backlog (signed-but-undelivered work — huge at the majors but cancellable if a sponsor kills a program), book-to-bill ratio (above 1.0 means the order book is growing), and billable utilization.[4] Federal work adds cost-reimbursement, cost-plus, and fixed-price contracts, where profit is thin and steady and the main risk is losing the contract at recompete.
• Grants and non-dilutive funding (crucial for nano and early biotech). Federal agencies fund research directly; for small firms, SBIR/STTR grants (Small Business Innovation Research / Small Business Technology Transfer) are cash that funds work without selling equity.[6]
• Milestones, licensing, and royalties (the high-margin, slow-arriving payoff). A patented material, molecule, or process can throw off royalties for years — the best outcome, but dependent on patent quality and freedom to operate. Out-licensing to a larger partner for an upfront payment plus milestones and royalties is the standard way a cash-poor lab monetizes a discovery.[6]

The defining financial reality across all three children is a long, cash-hungry gap between a promising result and a paying product — the "valley of death." For the many pre-revenue startups (dense in nano and biotech), the single most important number is cash runway versus burn rate; running out before the next data readout forces dilutive fundraising or a fire sale. For the services-heavy firms (dense in 541715), the useful metrics are backlog, book-to-bill, net service revenue (fee revenue excluding zero-margin pass-through costs), and margin. Average pay near $148,000–$185,000 across the children tells you the fixed-cost base is expensive talent.[2]

---

6. What drives demand

Demand for this level is really demand for outsourced research and for the capital that funds it — and it arrives through several channels that hit the children differently:

• Corporate and government outsourcing of specialized research is the through-line. Big pharma keeps shifting development work to CROs (industry estimates put large-pharma outsourcing near ~45% and rising), and agencies increasingly buy science and engineering rather than build it — a structural tailwind that most benefits 541715.[4]
• Biopharma R&D budgets and biotech funding cycles. More molecules in development means more trials to run; small-biotech trial funding is interest-rate-sensitive, making capital-market conditions the industry's main cyclical swing factor (the 2021–23 slump and 2025 recovery tracked the cost of capital more than any single scientific event).[3-biotech][4]
• The patent cliff. Large drugmakers face roughly $170 billion of revenue exposed to patent expirations by 2032, creating urgent, structural demand to acquire biotech pipelines.[3-biotech]
• Federal science and technology budgets. In fiscal 2024, five agencies (Defense, HHS, Energy, NASA, and the National Science Foundation) accounted for about 93% of federal R&D obligations — ~$181 billion — the dominant cyclical driver for the physical-sciences and government segment.[4] For nanotechnology specifically, the National Nanotechnology Initiative (NNI) is the funding backbone, and its request fell from a record $2.2 billion (FY2025) to $1.45 billion (FY2026) — a forward-looking headwind for grant-reliant labs.[6]
• Scientific waves. Advanced semiconductors and AI hardware (the strongest current pull on nano), obesity/metabolic drugs, cell and gene therapy, energy storage, and AI-enabled discovery are all magnets for both research spend and capital.[3-biotech][6]

---

7. Regulation

There is no single "R&D law." Oversight is applied to the work being done, and the regulatory stack differs by child:

• Human-subjects and clinical rules (heaviest in biotech and clinical CROs). Good Clinical Practice under the Food and Drug Administration (FDA) — 21 CFR Parts 50, 56, 312, and 812 — plus the Common Rule (45 CFR Part 46) and Institutional Review Board protections govern human trials; Good Laboratory Practice (21 CFR Part 58) governs nonclinical safety studies; animal research adds USDA and institutional oversight. The FDA's approval gate (IND → Phase I–III → NDA/BLA) is the main value-creating event for a drug program.[3-biotech][4]
• Product-by-product chemical and safety rules (nanomaterials). There is no single nanotechnology statute; nanomaterials are regulated under existing frameworks — EPA reporting under the Toxic Substances Control Act, FDA's product-specific pathways, and OSHA/NIOSH worker-exposure guidance.[6]
• Federal procurement and export controls (physical-sciences and government work). The Federal Acquisition Regulation (especially Part 35 on R&D contracting), export controls (ITAR and the EAR, with a fundamental-research exception), and the Bayh-Dole framework that lets contractors and universities retain rights to federally funded inventions.[4]
• A live geopolitical rule: the BIOSECURE Act. Signed into law in December 2025, it restricts federal dealings with named Chinese biotechnology "companies of concern," reshaping global CRO/CDMO (contract development and manufacturing organization) supply chains — a reshoring tailwind for U.S. and allied providers.[4]

The forward-looking regulatory questions are nanomaterial toxicity (likely rising scrutiny as materials scale into consumer use) and the stability of the federal funding and antitrust environment.

---

8. Consolidation

The level is fragmented in aggregate and consolidating in pockets — a classic barbell, and the pattern differs by child.

• The research layer is extraordinarily un-concentrated. At the level, the top four firms hold just 11.4% of receipts and the HHI is 62.2 — far below the ~1,500 "concentrated" threshold — reflecting thousands of small labs across three fields.[3]
• But sub-markets consolidate hard. The clinical-CRO tier (within 541715) is an oligopoly built by big deals: Thermo Fisher bought PPD for $17.4 billion (2021), ICON bought PRA for ~$12 billion (2021), Syneos went private for ~$7.1 billion (2023), and Labcorp spun off Fortrea (2023). Government-services firms are consolidating in parallel to buy scale and cleared talent.[4]
• Biotech's endgame is acquisition, not organic scale. Driven by the patent cliff, 2025 saw well over $200 billion of pharma M&A; large drugmakers buy de-risked pipelines rather than build them, and small biotechs sell because clearing late-stage trials is beyond their means.[3-biotech]
• Nanotechnology consolidates through strategic acquisition or licensing. The standard exit for a successful small nano lab is to be bought by a chemicals, semiconductor, or pharma acquirer that wants the team and patents — IPOs are the exception.[6]

Across all three, the realized return driver is usually an acquisition or a licensing royalty, not an initial public offering (IPO). The non-profit institutes and contractor-run federal labs are a permanent, unbuyable fixture that shapes competition without ever changing hands.[4]

---

9. Risks

• The valley of death (all children). Many projects work in the lab and never survive scale-up, clinical failure, or customer qualification. In biotech, only ~1 in 10 drugs entering Phase I wins approval.[3-biotech]
• Funding-cycle dependence. Grant-reliant firms (nano especially) are exposed to federal budget swings — the FY2026 NNI request fell sharply; biotech-trial demand is rate-sensitive; federal-services work is exposed to appropriations fights.[4][6]
• Cancellable backlog and customer concentration. A single sponsor or agency can scrap a trial or program, erasing future revenue overnight; a consolidating pharma client base concentrates leverage on the CROs.[4]
• Capital intensity and dilution. Pre-revenue micro-caps and private companies burn cash and raise equity repeatedly; dilution and outright failure are common in nano and clinical-stage biotech.[3-biotech][6]
• Talent-cost inflation. In a people business, wage inflation and turnover among cleared scientists, engineers, and clinical-research associates compress margins.[4]
• Regulatory, IP, and quality failure. An FDA warning letter, a data-integrity finding, an export-control violation, or a narrow/unenforceable patent can jeopardize a program's value.[4][6]
• Geopolitics cuts both ways. BIOSECURE helps domestic providers but disrupts supply chains mid-stream; export controls can close markets; overseas producers pressure commodity-nanomaterial pricing.[4][6]
• Measurement and "washing" risk. Federal business statistics omit government, university, and self-employed research, and some firms use "nano" or "AI" branding without material, defensible technology. Do not mistake broad sector exposure for direct ownership of the code's activity.[2]

---

10. How to invest and the outlook

Public routes — match the door to the child.

• Biotech (541714): diversified ETFs are the standard entry — XBI (equal-weight, closest to the research layer) and IBB (cap-weighted, skewed to the giants); individual large-caps (LLY, AMGN, GILD, VRTX) for lower-volatility, profit-backed exposure; individual clinical-stage names (ALNY, CRSP, RXRX) for the highest upside and wipeout risk.[3-biotech]
• Physical/engineering/life sciences (541715): the CRO complex (IQV, ICLR, MEDP, FTRE, CRL, NOTV) for the cleanest R&D-outsourcing exposure, and federal science-and-engineering contractors (LDOS, SAIC, AMTM, PSN, KBR, J, EXPO) for the physical-sciences half. Both trade on backlog growth, book-to-bill, and margins rather than dividends.[4]
• Nanotechnology (541713): mostly indirect — semiconductor-equipment and instrument makers (AMAT, LRCX, KLAC, ONTO, BRKR, VECO) and diversified materials leaders (BASF, DuPont), where nano is one growth driver inside a real business. Direct pure-plays are speculative micro-caps.[6]

Private routes are the deepest and most genuine exposure across all three children — VC and life-science funds, growth equity, corporate-venture partnerships, university technology transfer, royalty and venture-debt strategies, and PE ownership of the mid-tier CROs. The trade-off is illiquidity and long horizons, and the realistic payoff is an acquisition or a licensing royalty rather than a near-term IPO. Core diligence everywhere: IP ownership and freedom to operate, customer validation, cash runway versus burn, contract quality and backlog funding, and the path from prototype to repeat orders.[3-biotech][4][6]

Forward-looking judgment (not a reported fact). The level's long-term setup is constructive but uneven, and the case is strongest in the largest child. 541715 is structurally advantaged — rising outsourcing penetration, BIOSECURE-driven reshoring, AI adoption in trial design, and steady (if budget-cycle-exposed) federal demand — and it is nearly three-fifths of the industry. Biotech entering 2026 looks better than its 2022–24 trough, with a rebounding financing environment and an urgent patent cliff forcing acquisitions, but it remains among the highest-beta corners of the market. Nanotechnology has robust and broadening end-market demand (advanced semiconductors and AI hardware above all) but a shrinking federal funding request and almost no clean public vehicle. Net: treat 54171 as a quality-cyclical, high-skill services industry whose growth is real but geared to the biopharma and government funding cycles — and never mistake the $331 billion of receipts for the total amount of R&D the United States performs, or assume any listed company's full revenue belongs to this code.

---

Sources

1. U.S. Census Bureau, "2022 NAICS — 54171 / 541713 / 541714 / 541715: Research and Development in the Physical, Engineering, and Life Sciences" (industry definitions, scope, and 2017 code split). https://www.census.gov/naics/?input=54171&year=2022
2. U.S. Census Bureau, County Business Patterns, NAICS 54171 and children (establishments, employment, annual and Q1 payroll; coverage exclusions of government, non-employer, and self-employed), 2023. https://www.census.gov/programs-surveys/cbp.html
3. U.S. Census Bureau, 2022 Economic Census — Concentration by Largest Firms, NAICS 54171 and children (receipts, firm counts, CR4/CR8/CR20/CR50, HHI). Ground-truth level figures per Histometrics ingested stats (receipts $331.2B; 16,450 firms; CR4 11.4%; HHI 62.2). https://www.census.gov/programs-surveys/economic-census.html
4. Histometrics primer, NAICS 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): CRO/federal-services universe, outsourcing penetration ~45%, FAR/GCP regulation, CRO consolidation, BIOSECURE Act, and federal R&D obligations (~$181.4B / 93% across five agencies, FY2024). Draws on U.S. Census, NSF NCSES, FDA, FAR, and SEC filings.
5. National Center for Science and Engineering Statistics (NSF NCSES), "U.S. R&D Totaled $937 Billion in 2023 (2024 estimate $993 billion); Business R&D $722 Billion," 2025. https://ncses.nsf.gov/pubs/nsf26314
6. Histometrics primer, NAICS 541713 — Research and Development in Nanotechnology: indirect "picks-and-shovels" public universe, private nano-materials startups, NNI budget ($2.2B FY2025 request → $1.45B FY2026 request; ~$47B cumulative since 2001), TSCA/FDA/OSHA regulation, and acquisition-driven consolidation. Draws on U.S. Census, the National Nanotechnology Coordination Office, EPA, FDA, and SEC filings.
7. Histometrics primer, NAICS 541714 — Research and Development in Biotechnology (except Nanobiotechnology): listed clinical-stage and large-cap universe, XBI/IBB ETFs, ~$38B biotech VC (2025), FDA approval pathway, ~$170B+ patent cliff, and 2025 pharma M&A (>$200B). Draws on U.S. Census, NSF NCSES, FDA, NIH, FTC, and SEC filings. (Cited inline as [3-biotech].)